Recludix Pharma to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

SAN DIEGO, Sept. 17, 2026 /CourierPR/ -- Recludix Pharma, a clinical-stage company focused on developing inhibitors for challenging targets in inflammatory diseases, will present an overview of its work at the Stifel 2026 Virtual Immunology and Inflammation Forum. Nancy Whiting, the company’s CEO, and Ajay Nirula, the president and head of research and development, will deliver the presentation on Thursday, September 24, 2026, at 3:30 p.m. Eastern Time.

Recludix employs a unique drug discovery platform that integrates custom-generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. The company’s primary focus is on developing potent and selective inhibitors of challenging protein targets. Currently, Recludix is conducting a Phase 1 study of REX-8756, an oral inhibitor of STAT6, in a strategic partnership with Sanofi. Abnormal activation of STAT6 is implicated in various inflammatory diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.

In addition to the STAT6 inhibitor, Recludix is advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven inflammatory diseases. The company also has several other discovery programs in the pipeline. Recludix was named a 2024 Fierce 15 biotech company, highlighting its innovative approach and potential in the field of inflammatory diseases.

The presentation at the Stifel 2026 Virtual Immunology and Inflammation Forum will provide an update on the company’s progress and future plans. Attendees will gain insights into Recludix’s innovative drug discovery platform and the potential of its inhibitors in treating challenging targets in inflammatory diseases.

Recludix’s management team includes industry veterans with a proven track record of success. Former leaders of Seagen, Blueprint Medicines, and Lilly have joined forces to drive the company’s mission. The company’s approach to drug discovery and development positions it as a leader in the field, with a strong focus on innovation and selectivity.